Paul Chamberlain
pharmaceutical industry
Alethia Biotherapeutics
Canada
Biography
Paul Chamberlain is a biopharmaceutical product development specialist, with particular interests in IND-enabling development of therapeutic monoclonal antibody-based products. Paul has accumulated substantial industrial experience in the development of biopharmaceutical products. This experience includes a broad scientific background, incorporating the application of analytical and bioanalytical technologies to the quality control of therapeutic proteins. During the early 1980’s, Paul was employed as an analytical scientist within the Biotechnology department of SmithKline Beecham. Following work on recombinant fibrinolytic proteins, Paul spent 7 years in the Monoclonal Antibody Unit using hybridoma technology to prepare monoclonal antibodies for research and development applications. Having gained 18 years R&D experience, Paul then moved into Regulatory Affairs. His position as a European Regulatory Specialist with Amgen included responsibilities for both marketed and investigational recombinant proteins
Research Interest
Paul Chamberlain is a biopharmaceutical product development specialist, with particular interests in IND-enabling development of therapeutic monoclonal antibody-based products. Paul has accumulated substantial industrial experience in the development of biopharmaceutical products. This experience includes a broad scientific background, incorporating the application of analytical and bioanalytical technologies to the quality control of therapeutic proteins. During the early 1980’s, Paul was employed as an analytical scientist within the Biotechnology department of SmithKline Beecham. Following work on recombinant fibrinolytic proteins, Paul spent 7 years in the Monoclonal Antibody Unit using hybridoma technology to prepare monoclonal antibodies for research and development applications. Having gained 18 years R&D experience, Paul then moved into Regulatory Affairs. His position as a European Regulatory Specialist with Amgen included responsibilities for both marketed and investigational recombinant proteins
